# US 2024/0093159 A1 · Virus-like particles and methods of production thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0093159 A1
- Document ID: US20240093159A1
- Status: Published application
- Kind: A1
- Application number: 18/038,585
- Filed: 2021-11-26
- Published: 2024-03-21
- Earliest claimed: 2020-11-30
- Assignees: University of Dundee
- Applicants: University of Dundee
- Inventors: John FOERSTER
- Web page: https://patentgrep.com/patent/US20240093159A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- C07K 14/005: from viruses
- C07K 14/32: from Bacillus (G)
- C07K 14/54: Interleukins [IL]
- C07K 14/5437: {IL-13}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/88: Lyases (4.)
- C12Y 301/21001: Deoxyribonuclease I (3.1.21.1)
- C12Y 301/27003: Ribonuclease T1 (3.1.27.3)
- C12Y 406/01: Phosphorus-oxygen lyases (4.6.1)
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/60: {characteristics by the carrier linked to the antigen}
- C07K 2319/50: containing protease site
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2730/10123: Virus like particles [VLP]
- C12N 2730/10151: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.

## Claims

### Claim 1

A virus-like particle (VLP) comprising:
One or more hepatitis B capsid proteins
One or more pairs of binding proteins, each pair of binding proteins comprising a first binding protein and a second binding protein, wherein the pair of binding proteins comprises a bacterial toxin and its inhibitor
One or more functional molecules
wherein each hepatitis B capsid protein is attached to a first binding protein, wherein each functional molecule is attached to a second binding protein, and wherein the first and second binding proteins are bound to each other.

### Claim 2 (depends on 1)

A VLP according to claim 1, wherein the first binding protein is the bacterial toxin inhibitor, and the second binding protein is the bacterial toxin.

### Claim 3 (depends on 1, 2)

A VLP according to claim 1 or 2, wherein each functional molecule is indirectly attached to a second binding protein via a third binding protein, preferably the third binding protein is protein G.

### Claim 4 (depends on 1, 2, 3)

A VLP according to claim 1, 2 or 3, wherein the first binding protein comprises a chemical modification, optionally wherein the chemical modification is attached to a second functional molecule.

### Claim 5

A VLP according to any preceding claim, wherein each functional molecule may be the same or different, preferably wherein the functional molecule is selected from: a protein or non-protein antigen or an epitope thereof, an antigen binding protein, or a flourescent molecule.

### Claim 6 (depends on 3)

A VLP according to claim 3, wherein each functional molecule is an antigen binding protein, preferably wherein the antigen binding protein is selected from an antibody or binding fragment thereof, an antibody mimetic, and an aptamer, preferably wherein the antigen binding protein is an antibody, preferably an antibody which is capable of binding an antigen of interest.

### Claim 7

A virus-like particle (VLP) comprising:
One or more viral capsid proteins
One or more first binding proteins comprising a chemical modification, wherein each first binding protein is a bacterial toxin inhibitor;
One or more functional molecules
wherein each viral capsid protein is attached to a first binding protein, and wherein each chemical modification is attached to a functional molecule.

### Claim 8 (depends on 7)

A VLP according to claim 7, wherein the viral capsid protein is a Hepatitis B capsid protein.

### Claim 9 (depends on 7, 8)

A VLP according to claim 7 or 8, further comprising a second binding protein, wherein the second binding protein is bound to the first binding protein, optionally wherein the second binding protein is attached to a second functional molecule.

### Claim 10 (depends on 9)

A VLP according to claim 9, wherein the second binding protein is a bacterial toxin, preferably a bacterial toxin which binds to the bacterial toxin inhibitor.

### Claim 11 (depends on 9, 10)

A VLP according to claim 9 or 10, wherein each second functional molecule is indirectly attached to a second binding protein via a third binding protein, preferably the third binding protein is protein G.

### Claim 12 (depends on 7, 8, 9, 10, 11)

A VLP according to any of claims 7-11, wherein each functional molecule may be the same or different, preferably wherein the functional molecule is selected from: a protein or non-protein antigen or an epitope thereof, an antigen binding protein, or a flourescent molecule.

### Claim 13 (depends on 11)

A VLP according to claim 11, wherein the each functional molecule is an antigen binding protein, preferably wherein the antigen binding protein is selected from an antibody or binding fragment thereof, an antibody mimetic, and an aptamer, preferably wherein the antigen binding protein is an antibody, preferably an antibody which is capable of binding an antigen of interest.

### Claim 14

A VLP according to any preceding claim, wherein the bacterial toxin inhibitor is selected from Im7, Im8, Im9, Im2, and Barstar.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6)

A VLP according to any of claim 1-6, or 10-14, wherein the bacterial toxin is a bacterial nuclease, preferably selected from: ColE7, ColE8, ColE9, ColE2, and Barnase.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15)

A VLP according to any of claim 1-6 or 10-15, wherein the bacterial toxin and its inhibitor are Barnase and Barstar, preferably wherein the Barstar amino acid sequence comprises one or more of the following substitutions: C40A, C82A, and I87E, and/or wherein the amino acid sequence of Barnase comprises the following substitution: E73W.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15)

A VLP according to any of claim 1-6 or 10-15, wherein the bacterial toxin and its inhibitor are ColE7 and Im7, preferably wherein the amino acid sequence of Im7 comprises the following substitution: F41L, and/or wherein the amino acid sequence of ColE7 comprises one or more of the following substitutions: Arg538Ala, Glu542Ala, and His569Ala.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6)

A VLP according to any of claim 1-6, or 8-17, wherein the first binding protein is inserted into the major immunodominant region of the hepatitis B capsid protein, preferably the first binding protein is inserted between amino acid residues 76 and 80 of the major immunodominant region of the hepatitis B capsid protein.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6)

A VLP according to any of claim 1-6, or 8-18, wherein the hepatitis B capsid protein comprises an amino acid sequence with the following amino acid deletions: E77 and D78.

### Claim 20 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A VLP according to any of claims 4-19, wherein the chemical modification is an alkane having an amine group, preferably a 1-10 carbon alkane having an amine group, preferably wherein the chemical modification is selected from DEAE or octylamine.

### Claim 21 (depends on 5, 12)

A VLP according to claim 5 or 12, wherein the non-protein antigen is selected from a: sugar, lipid, carbohydrate, or small molecule chemical.

### Claim 22 (depends on 5, 12)

A VLP according to claim 5 or 12, wherein the protein antigen is derived from an infectious agent, preferably wherein the protein antigen is derived from a virus, bacterium, fungus, protozoan, archaeon, preferably wherein the protein antigen is derived from a virus, preferably wherein the virus is selected from: Adeno-associated virus, Chikungunya virus, Crimean-Congo hemorrhagic fever virus, Dengue virus, Ebolavirus, Echovirus, Encephalomyocarditis virus, Epstein-Barr virus, Hantaan virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Human adenovirus, Human astrovirus, Human coronavirus, Human cytomegalovirus, Human enterovirus, Human herpesvirus, Human immunodeficiency virus, Human papillomavirus, Human parainfluenza, Human respiratory syncytial virus, Human rhinovirus, Human torovirus, Influenza A virus, Influenza B virus, Influenza C virus, Japanese encephalitis virus, Polyomavirus, Kunjin virus, Lassa virus, Measles virus, Molluscum contagiosum virus, Mumps virus, Nipah virus, Poliovirus, Rabies virus, Rotavirus A, Rotavirus B, Rotavirus C, Rubella virus, Sagiyama virus, Salivirus A, Sapporo virus, Sindbis virus, Toscana virus, Uukuniemi virus, Varicella-zoster virus, Venezuelan equine encephalitis virus, Vesicular stomatitis virus, Western equine encephalitis virus, West Nile virus, Yellow fever virus, Zika virus, preferably wherein the protein antigen is derived from a coronavirus, preferably from SARS-CoV-2, preferably the protein antigen is the whole or part of a spike protein derived from SARS-CoV-2, or the whole or part of a nucleocapsid protein derived from SARS-CoV-2.

### Claim 23 (depends on 5, 12)

A VLP according to claim 5 or 12, wherein the protein antigen is derived from a non-infectious agent, preferably wherein the protein antigen is derived from an inflammatory molecule, a molecule causing degenerative changes in nervous, cartilage or bone tissue, or a molecule causing worsening of a neoplastic disease, preferably wherein the protein antigen is an inflammatory molecule selected from a chemokine, cytokine, or protease, preferably wherein the protein antigen is selected from: IL1, IL2, Il3, Il4, IL5, Il6, Il7, IL8, IL9, IL10, IL11, IL12, IL13, IL17, IL33, TNFα, TNFβ, IFNα, IFNβ, IFNγ, G-CSF, GM-CSF, M-CSF, erythropoietin, and TGFβ, preferably wherein the protein antigen is the whole or part of IL13, IL17 or IL33.

### Claim 24 (depends on 5, 12)

A VLP according to claim 5 or 12, wherein the flourescent molecule is selected from: GFP, EBFP, EBFP2, Azurite, GFPuv, T-saphhire, Cerulean, CFP, mCFP, mTurquoise2, CyPet, mKeima-red, tagCFP, AmCyan1, mTFP1, midoriishi cyan, turboGFP, tagGFP, emerald, azami green, ZsGreen1, YFP, tagYFP, EYFP, topaz, venus, mCtrine, YPet, turboYFP, ZsYellow1, Kusabira Orange, mOrange, allophycocyanin, mkO, RFP, turboRFP, tdTomato, tagRFP, dsRed, mStrawberry, turboFP602, asRed2, J-red, R-phycoerythrin, B-phycoerythrin, mCherry, HcRed, Katusha, P3, peridin chlorophyll, mKate, turboFP635, mPlum, mRaspberry, preferably wherein the flourescent molecule is GFP.

### Claim 25

A capsid fusion protein comprising a viral capsid protein fused to a binding protein, wherein the binding protein is a bacterial toxin inhibitor.

### Claim 26

A functional fusion protein comprising a functional molecule fused to a binding protein wherein the binding protein is a bacterial toxin.

### Claim 27

A functional fusion protein comprising a first binding protein fused to a further binding protein, wherein the first binding protein is a bacterial toxin, and the further binding protein is able to bind to functional molecules that are antigen binding proteins.

### Claim 28 (depends on 25, 26, 27)

One or more nucleic acids encoding the capsid fusion protein according to claim 25 or the functional fusion protein according to claim 26 or 27.

### Claim 29 (depends on 28)

One or more vectors comprising the one or more nucleic acids of claim 28.

### Claim 30 (depends on 28, 29)

A host cell comprising the one or more nucleic acids of claim 28 or the one or more vectors of claim 29.

### Claim 31

A host cell comprising one or more vectors, the one or more vectors comprising a first nucleic acid encoding a hepatitis B capsid protein attached to a first binding protein; and a second nucleic acid encoding a functional molecule attached to a second binding protein; wherein the first and second binding proteins are capable of binding to each other.

### Claim 32

A host cell comprising one or more vectors, the one or more vectors comprising a first nucleic acid encoding a viral capsid protein attached to a first binding protein; and a second nucleic acid encoding a functional molecule; wherein the functional molecule is capable of binding to the first binding protein via a chemical modification of the first binding protein.

### Claim 33

A process of producing a virus-like particle (VLP) in a single host cell comprising:
(a) Providing a host cell comprising one or more vectors, wherein the one or more vectors comprise:
(i) a first nucleic acid encoding a viral capsid protein attached to a first binding protein; and
(ii) (a) a second nucleic acid encoding a functional molecule optionally attached to a second binding protein; and/or
(b) a third nucleic acid encoding a second binding protein attached to a third binding protein;
(b) Culturing the host cell under conditions to express the proteins from the first, second and/or third nucleic acids respectively;
(c) Forming virus-like particles from the proteins.

### Claim 34

A process of producing a virus-like particle (VLP), comprising;
(a) Providing a first host cell comprising one or more vectors, wherein the one or more vectors comprise:
(i) a first nucleic acid encoding a hepatitis B capsid protein attached to a first binding protein, wherein the first binding protein is a bacterial toxin inhibitor;
(b) Providing a one or more further host cell(s) comprising one or more vectors, wherein the one or more vectors comprise:
a second nucleic acid encoding a functional molecule optionally attached to a second binding protein, wherein the second binding protein is a bacterial toxin; and/or
(ii) a third nucleic acid encoding a second binding protein attached to a third binding protein, wherein the second binding protein is a bacterial toxin;
(c) Culturing the host cells under conditions to express the proteins from the first, second and/or third nucleic acids respectively;
(d) Recovering the proteins;
(e) Mixing the proteins to form virus-like particles.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

An immunogenic composition comprising the virus-like particle of any of claims 1-25.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 35)

A virus-like particle (VLP) of any of claims 1-24, or an immunogenic composition of claim 35 for use as a medicament.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 35)

A virus-like particle (VLP) of any of claims 1-24, or an immunogenic composition of claim 35 for use in the prevention and/or treatment of infectious diseases, cardiovascular diseases, cancer, inflammatory diseases, autoimmune diseases, neurological disease, rheumatological degenerative disease, or addiction.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the virus-like particle (VLP) of any of claims 1-24 in research, or in the diagnosis of a disease.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of diagnosing a disease in a subject comprising:
(a) Providing a virus like particle according to any of claims 1-24, wherein the functional molecule is an antibody directed towards an antigen derived from a disease causing agent;
(b) Mixing the virus like particle with a suitable sample from the subject;
(c) Detecting whether the virus like particle precipitates;
(d) Diagnosing the presence of a disease if the VLP precipitates.
